Law360, New York (October 31, 2011, 8:50 PM ET) -- The Ninth Circuit on Monday affirmed a ruling denying Amylin Pharmaceuticals Inc.'s request to block Eli Lilly & Co. from allegedly violating a joint marketing agreement and breaching antitrust laws by selling Amylin's diabetes drug alongside rival treatments made by Boehringer Ingelheim GmbH.
A three-judge panel ruled that a California federal court had applied the law correctly when it denied Amylin's motion because the company had failed to show how it would suffer the irreparable harm that would warrant a preliminary injunction.
Amylin had told the...
Amylin Can't Block Lilly's Rival Drug Sales: 9th Circ.
To view the full article, take a free trial now.
